Research News for November 2, 2022
advertisement
- Functional and metabolic alterations of gut microbiota in children with new-onset type 1 diabetes
- A world-first gene therapy clinical safety trial for type 1 diabetes
- Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA
- Altered microvasculature in pancreatic islets from subjects with type 1 diabetes
- New therapeutic approaches for type 1 diabetes: Disease-modifying therapies (Full text HTML, PDF)
- Role of miR-155 in inflammatory autoimmune diseases: a comprehensive review
- Polygenic Health Index, General Health, and Pleiotropy: Sibling Analysis and Disease Risk Reduction (Full text HTML, PDF)
- PDE12 in type 1 diabetes (Full text HTML, PDF)
- Clinical signs of type 1 diabetes are associated with type 2 diabetes marker transcription factor 7-like 2 polymorphism
- Gut Microbiota and Their Associated Metabolites in Diabetes: A Cross Talk Between Host and Microbes-A Review
- A Single Nucleotide Polymorphism (rs3811792) Affecting Human SCD5 Promoter Activity Is Associated with Diabetes Mellitus
- Using single cell multi-omics screening of human fetal pancreas to identify novel players in human beta cell development
- HERV-K Envelope Protein Induces Long-Lasting Production of Autoantibodies in T1DM Patients at Onset in Comparison to ZNT8 Autoantibodies
- Islet-specific CD8+T cells gain effector function in the gut lymphoid tissues via bystander activation not molecular mimicry
